Director, CEO #
Dr. Michael Raymont #
Dr. Raymont’s career has spanned leadership roles in venture capital, agricultural and healthcare investment, tech company leadership and senior Government service, where he ran the National Research Council (NRC), Canada’s largest R&D organization. With a background in both science and business, Dr. Raymont has advised corporations and governments, worked extensively internationally and has sat on the boards of over 50 public and private companies.
Director, CFO #
Chand Jagpal #
Public Company Management and Accounting Professional including Financial, Disclosure and Compliance Responsibilities in the medical cannabis, agriculture, biotech, nutraceuticals, real estate development and business software systems industries with 20+ years of experience.Past experience includes Director and CEO of Grand Peak Capital Corp., a publicly listed Venture Capital Corp investing in portfolio of Resource and Technology Corps.
Director #
Rob Kang #
25+ years of public practice and company management advising corporations and their executives on financing, mergers, acquisitions, going public transactions, continuous disclosure obligations, and corporate governance. Rob spent 15 years as the Director of Listings for the TSX Venture Exchange.
Director #
Katie Shelton-Innes #
Katie has been advising and raising funds for growth companies, since 2005, working for various full-service small-mid cap investment banks. She currently sits on the boards of Northern Leaf, Change Agronomy, and Alinova Biosciences. Katie has a first class honours degree in Economics from Loughborough University, graduating top of her class. She qualified as an accountant in 2004 and is also is involved with various charity ventures, including one she founded during lockdown relating to the sustainable fashion industry.
Non-Executive Director #
Mike Thompson MBE #
25+ years in the Public Health, serving as CEO at The Association of the British Pharmaceutical Industry (ABPI), and in senior roles at GSK and Unilever. His service to the biotech, pharma industry and wider life sciences, led to an MBE in 2021. Thompson has worked closely with No 10, Treasury, DHSC, BEIS and the Office of Life Sciences. This has delivered tangible policy outcomes such as the Life Sciences Industrial Strategy, which ultimately secured two Sector Deals bringing billions of pounds of new investment to the UK. During his time at GSK (1995 – 2015), Thompson held senior roles at Global, European Regional, and UK levels of the company.
